Get Adobe Flash player
Special Report Oncotechnology Track has been carefully structured to facilitate critical discussions between medical physicists, biomedical engineers, cancer scientists, clinicians and other stakeholders, providing a platform for emerging technologies and their potential impact on cancer diagnostics, therapy and research. The Education Track covers one of the cornerstones of good cancer treatment and care, including state-of-the art guidelines for different disease stages of frequent tumour types such as breast, colorectal and lung cancer, as well as less frequent cancers. With a growing emphasis on how best to tackle advance disease in cancer patients, Educational Symposia are the must-attend sessions in this respect. The Oncopolicy Track is regarded as the forum for guiding evidence- based policymaking in Europe. At Amsterdam, the Track will continue to gather all stakeholders to address and tackle matters of prime importance to the European cancer community head-on, as well as promote and foster continued improvement at EU level. The Track’s theme Oncopolicy 2020 is set to stimulate debate around the hottest topics affecting all cancer stakeholders. is why young oncology mentorship sessions given by José Baselga, Sarah Faithfull, Peter Naredi, Graeme Poston, Jean-Charles Soria and Vincenzo Valentini are being offered for the first time at the ECC 2013, to help bridge this gap. Similarly, both the Patient Advocacy/Ethics Track and the Oncology Nursing Track are fully integrated within the core Scientific Programme to ensure full participation of all disciplines on topics of shared concern to cancer patients, advocates and professionals alike. This also enables participation of cancer nurses in all programme sessions, a crucial step for identifying future directions aimed at improved patient care across Europe. New Data The Regulatory Track includes a number of highly relevant sessions and talking points, including: ‘The dilemma of cross-over in clinical trial design of agents of obvious activity’, ‘Outcome measures in clinical trial design’ and ‘Cancer pharmaceutics’, as well as the debate entitled: ‘The EU Directive has harmed European Clinical studies’. Late-breaking abstracts will form the core of the Presidential Sessions in Amsterdam, as well as featuring in proffered paper sessions. The number of oral presentation slots has increased to provide a leading showcase for these latest developments in practice-changing studies of new and significant scientific importance. These data will help accelerate the promise of personalised medicine, impact directly on our patients through more effective prevention strategies, earlier diagnosis and better treatment modalities, as well as succeed in bringing cutting- edge data back to Europe. The Young Oncologists Track emphasises the importance of catering to the needs of young physicians, practitioners and scientists – critical for the development of the next generation of cancer research and treatment specialists. It includes sessions such as ’How to be a happy oncologist’ and the ‘Integration of genetic information into daily practice’. Wider, career-orientated support and information to help shape and encourage the interests and future work of young oncologists, is often lacking at congresses, as is mentoring and guidance from experienced scientists in avoiding mistakes that they themselves have made during their own career learning curve. That 8 The best discussions are also triggered by abstracts. Some of the best new data in Europe and beyond will be showcased at the ECC 2013. An extensive amount of new data will feature as proffered papers – regular abstracts have increased by 38 percent since the 2011 Congress in Stockholm – and there is no doubt that stimulating and influential dialogue will emerge as a direct result. A comprehensive, stimulating, rigorous and highly educational scientific experience, irrespective of participants’ roles or focus in oncology is guaranteed for all participants. The 17th ECCO, 38th ESMO, 32nd ESTRO European Cancer Congress forms the foremost milestone on the world congress agenda in progressing the fight against cancer through the multidisciplinary approach. n Eur op ean On c olog y & H a e matolog y